Clinical Trial Update: 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Lutetium-177 PSMA-617 with androgen receptor–directed therapy in progressive metastatic castration-resistant prostate cancer has posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)
• Androgen receptor-directed therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-09